NIH Forecasts $12M for RNomics Technology Enhancement Centers — and Quietly Re-Cut a $151M Program by Risk Tier

Academic PIs running RNA labs got an unusual amount of warning on August 5: NIH posted a Grants.gov forecast for RFA-RM-28-005, the RNomics Technology Enhancement Centers, promising $12 million across four cooperative agreements with applications due February 1, 2027 — roughly eighteen months of lead time.

Forecasts are not solicitations, and NIH says so in the notice itself: "Applications are not being solicited at this time. This notice is being provided to give potential applicants time to develop meaningful collaborations and strong projects." But a forecast carrying an award ceiling, an award count, an estimated funding total, a projected synopsis date and a projected project start date is closer to a blueprint than a teaser. Line all four RNomics forecasts up against the concept the NIH Council of Councils approved in December, and the program's internal architecture becomes legible in a way it wasn't a week ago.

What the August 5 forecast actually puts on the table

The Grants.gov listing for opportunity 363473 is specific. RFA-RM-28-005 will establish collaborative RNomics Technology Enhancement Centers — RTECs — with $12,000,000 in estimated first-year funding, four anticipated awards, and a $2,000,000 per-award ceiling. The instrument is a cooperative agreement, not a standard grant. The assistance listing is 93.310, Trans-NIH Research Support, the Common Fund's usual vehicle. Program contact is cfrnomics@od.nih.gov.

The dates matter more than the dollars right now. NIH projects the full NOFO posting on October 1, 2026, applications due February 1, 2027, and award plus project start on December 1, 2027. That start date is the tell: December 1, 2027 falls in fiscal 2028, which is why the RFA carries an RM-28 prefix.

The scientific scope is narrower than "RNA technology" implies. RTECs are for "further develop[ing] existing technologies with demonstrated feasibility" — strengthening experimental and computational tools for measuring, mapping and testing RNA in cells and tissues, with an explicit obligation to deliver "measurable improvements and support broad community use." The forecast names three priority areas: end-to-end RNA sequencing paired with quantitative modification mapping; comprehensive analysis of RNA sequence, structure, modification, interactions, localization, dynamics and function; and molecular and biochemical tools for RNA manipulation, processing and functional testing.

One eligibility detail is easy to miss. The forecast's applicant list includes non-domestic entities — foreign institutions — alongside public and private universities, small businesses, and for-profits. Common Fund center awards do not always open that door.

The four RFAs are one budget line, cut four ways

RNomics is not a single solicitation. Four forecasts posted together on August 5, and their numbers only make sense read as a set:

That totals $30 million in year one across 18 awards. The December 2025 concept clearance one-pager put the RNomics program at $151.25 million over five years — $30.25 million annually, FY27 through FY31, with $250,000 of each year reserved for NIH staff salary, travel and NIH-organized workshops. Subtract that $250K administrative line and the concept's annual research budget is exactly $30 million. The four August forecasts reproduce it to the dollar.

Lead institutes are distributed rather than centralized: NHGRI and NIGMS on sequencing technology, NIAID, NIDA and NCI on molecular and computational tools, NIEHS and NIA on standards, NIEHS and NHGRI on the coordinating center. Over five years the concept allocates $70M to sequencing technology, $30M to molecular and computational tools, $27M to standards, and $23M to coordination — with the coordinating center's share ramping from $2M in year one to $7M in year five as data volume accumulates.

Read the restructure: NIH re-cut the program by risk, not by topic

Here is the part worth an hour of a PI's attention.

The approved concept described Initiative 1 as "RNA Sequencing Technology" at $14M/year and Initiative 2 as "RNA Molecular and Computational Tools" at $6M/year — a split by subject matter. The forecasts describe something different: Technology Enhancement Centers at $12M and Transformative Technologies at $8M. Same $20 million. Different partition.

The new line is drawn by maturity. RTECs (RFA-RM-28-005) fund technologies "with demonstrated feasibility." Transformative Technologies (RFA-RM-28-006) funds the opposite — "early-stage, high-risk ideas not yet demonstrated at scale or in biologically relevant systems," structured as phased projects where Phase 1 milestone completion gates evaluation for Phase 2. Both RFAs cover sequencing, modification detection, functional analysis and computational tools. Neither owns a subject area.

That reads as a direct answer to the Council of Councils. The December concept was a revision; an earlier version went to Council in September 2025 and came back with concerns about "the feasibility of the program as presented, specifically related to the timing and potential interdependency of the proposed initiatives, the broad scope of the program, and concerns about the high-risk nature of some of the proposed initiatives." Segregating de-risked center work from speculative phased work — with ten small $500K-ceiling awards absorbing the speculative half — is what a program office does when reviewers say a portfolio is too risky and too entangled.

For applicants this changes the central question. It is no longer "does my project fit sequencing or functional tools." It is "can I demonstrate feasibility today, or am I still proving the concept?" Answer that wrong and you are in the wrong review pool: a mature platform submitted to -006 gets scored against a $500K ceiling it doesn't need, and a promising-but-unproven method submitted to -005 gets marked down against a center RFA that demands measurable improvement and immediate community distribution.

The timeline moved, and NIH's own program page hasn't caught up

The Common Fund's RNomics page still tells visitors that funding opportunities are "expected to be announced in 2027." The August 5 forecasts say the NOFOs post October 1, 2026 — with the earliest deadlines four months later. Anyone relying on the program page will start building a consortium roughly a year late.

There is also a quiet fiscal slip. The December concept table budgeted the first $30.25M tranche in FY27. Every forecast now projects a December 1, 2027 project start, which lands in FY28, and the RFA numbering was assigned accordingly. Money the concept placed in FY27 is now landing a fiscal year later. That is common for Common Fund launches and not cause for alarm — but a PI planning bridge funding or a postdoc hire around an FY27 start should re-plan around late 2027 at the earliest.

Why NIH is spending $151M on RNA measurement rather than RNA biology

The rationale is a measurement gap, stated plainly in the concept document. RNA carries more than 170 chemically distinct modifications affecting stability, structure, localization and function, and "current tools cannot adequately sequence RNA or detect these modifications." A 2024 National Academies report declared that "RNA science stands at a critical crossroads."

So the deliverable is not a discovery. It is an "RNomics Toolkit" — advanced RNA sequencers, synthetic RNA standards, molecular tools for functional analysis, computational models, harmonized data standards, first-of-their-kind reference datasets, and clinically relevant RNA biomarkers. That framing should shape aims. A competitive RTEC application is not "we will use better RNA sequencing to understand disease X." It is "we will deliver a benchmarked, distributable capability that other labs adopt," with adoption metrics attached.

This is the same infrastructure-first posture NIH has taken across recent Common Fund launches — the pattern we traced in NIH's $150 million commitment to human-based research methods, where the money went to validated, transferable platforms rather than individual hypothesis-driven projects. It is also distinct from PRIMED-AI, the Common Fund's RM-27-series precision-medicine AI program whose center RFAs close in October 2026. Different series, different councils, different money.

What to do with eighteen months

Cooperative agreements carry obligations that standard R01s don't: substantial NIH programmatic involvement, consortium-wide data standards set by the ROC Center, and benchmarking coordinated across awardees. Three things are worth doing before the October 1 NOFO drops.

Decide your tier now. Feasibility-demonstrated work goes to -005 at up to $2M. Unproven work goes to -006 at up to $500K with a Phase 1 milestone gate. Pick before you write.

Build the consortium, not the aims. NIH said the forecast exists so applicants can "develop meaningful collaborations." Four RTEC awards against a field this size means partnership breadth is a differentiator — and foreign institutions are eligible.

Line up your benchmarking story. RFA-RM-28-007 will fund distributable reference standards for modified nucleosides and oligonucleotides specifically so tools can be compared across labs and platforms. An RTEC application that already names how it will be externally validated is answering a question reviewers will otherwise ask.

Email cfrnomics@od.nih.gov to get on the program listserv, then track what else NIH is putting into RNA measurement and sequencing infrastructure this cycle: search live RNA sequencing technology solicitations on Granted. Forecasts convert to NOFOs with little fanfare, and the four-month window between October 1 and February 1 is not enough time to assemble a center from scratch.